Clinical trials: Neoplasms by Site
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 2A study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON ATLAS (NCT07870746)
- Testing
- 177Lu-TLX250
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Hematologic Malignancies, Adult
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198.
- Trial name
- NCT06645886
- Testing
- KQB198, Dasatinib
- Where
- 29 sites in United States, France and 6 more
- Volunteers
- 13 people
- Sponsor
- Kumquat Biosciences Inc.
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or…
- Trial name
- RAINFOL-03 (NCT07166094)
- Testing
- Rina-S, IC
- Where
- 178 sites in United States, Australia and 17 more
- Volunteers
- 660 people
- Sponsor
- Genmab
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Non Small Cell Lung Cancer
Understanding Evidence-Based Practice Patterns in Advanced NSCLC
The overarching objective of this study is to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-base and personalized treatment of…
- Trial name
- NCT03107156
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carevive Systems, Inc.
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.
- Trial name
- INSPECT (NCT06380361)
- Testing
- BioSpy System
- Where
- 2 sites in Australia, France
- Volunteers
- 30 people
- Sponsor
- Sensome
Non Small Cell Lung Cancer
Performance Status During Treatment With Pemetrexed in Patients With NSCLC
The primary research objective of this observational study in pretreated patients with NSCLC of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second cycle of second-line treatment with single…
- Trial name
- PERFORMANCE (NCT00540241)
- Testing
- Pemetrexed
- Where
- Germany
- Volunteers
- 542 people
- Sponsor
- Eli Lilly and Company
Breast Tumour
Fluorescence-guided Resection in Breast Cancer
This is an explorative phase II study to investigate the suitability of PD L 506 in the specific intra-operative detection of breast tumour tissue.
- Trial name
- NCT01110954
- Testing
- PD L 506
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- photonamic GmbH & Co. KG
Metastatic Non-small Cell Lung Cancer
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
This study is a multi-center, open-label, dose-finding phase Ib clinical study with extension phase, which is aimed at evaluating the efficacy and safety of GB226 combined with fruquintinib in treatment of relapsed or metastatic…
- Trial name
- NCT03976856
- Testing
- GB226, Fruquintinib
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Genor Biopharma Co., Ltd.
Advanced or Metastatic NSCLC
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell…
- Trial name
- TROPION-Lung04 (NCT04612751)
- Testing
- Datopotamab deruxtecan, Durvalumab, Carboplatin
- Where
- 42 sites in United States, Belgium and 6 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection
Esophageal cancer is a highly aggressive malignancy with poor prognosis, ranking as the sixth leading cause of cancer-related deaths worldwide, particularly prevalent in regions such as East Asia and East Africa.
- Trial name
- NCT06895551
- Where
- China
- Volunteers
- 1,069 people
- Sponsor
- Singlera Genomics Inc.
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin…
- Trial name
- NCT00612586
- Testing
- Enzastaurin, Leucovorin (LV), 5-fluorouracil (5-FU)
- Where
- 26 sites in United States, Austria and 4 more
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00401570
- Testing
- Volociximab, Gemcitabine
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Adult, Lung Cancer
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating…
- Trial name
- NCT06519669
- Testing
- GT201 injection
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Lung Neoplasms
Circulating Tumor DNA in Surgical Lung Cancer Patients
Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.
- Trial name
- NCT03081741
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shenzhen Gene Health Bio Tech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.